Financial Deals - Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
![kite pharmaceuticals kite pharmaceuticals](http://logosandbrands.directory/wp-content/themes/directorypress/thumbs/Kite-Pharma-Inc.-logo.jpg)
The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions. Kite Pharma Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings.The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. Kite Pharma is headquartered in Santa Monica, California, the US. The company has operational presence in the Netherlands and the US.
![kite pharmaceuticals kite pharmaceuticals](https://www.spcinc.com/wp-content/uploads/2019/04/rchs-kitepharma-9538.jpg)
![kite pharmaceuticals kite pharmaceuticals](https://www.pharmasalmanac.com/hubfs/images/kite%20pharma.png)
The company developed engineered autologous T-cell therapy (eACT) technology platform that allows to strengthen patient’s own immune system to target and kill cancer cells.It works in collaboration with various institutes and companies.
KITE PHARMACEUTICALS TRIAL
It offers KTE-C19 in a critical trial for the treatment of refractory, aggressive non-Hodgkin Lymphoma (NHL).Kite Pharma also provides early research and product development services. Kite Pharma Inc (Kite Pharma) is a bio-pharmaceutical company that discovers and develops cancer immunotherapy products.The company concentrates on chimeric antigen receptors (CAR) and T cell receptors (TCR) engineered cell therapies.